GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (BSP:B1MR34) » Definitions » Cyclically Adjusted Revenue per Share

Biomarin Pharmaceutical (BSP:B1MR34) Cyclically Adjusted Revenue per Share : R$25.79 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Biomarin Pharmaceutical's adjusted revenue per share for the three months ended in Mar. 2024 was R$8.108. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$25.79 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Biomarin Pharmaceutical's average Cyclically Adjusted Revenue Growth Rate was 9.60% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 14.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Biomarin Pharmaceutical was 34.80% per year. The lowest was 11.90% per year. And the median was 15.30% per year.

As of today (2024-05-01), Biomarin Pharmaceutical's current stock price is R$213.90. Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$25.79. Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio of today is 8.29.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomarin Pharmaceutical was 44.11. The lowest was 7.88. And the median was 17.25.


Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Chart

Biomarin Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 17.76 23.06 23.76 24.72

Biomarin Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 23.77 23.20 25.45 24.72 25.79

Competitive Comparison of Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio falls into.



Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Biomarin Pharmaceutical's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8.108/129.4194*129.4194
=8.108

Current CPI (Mar. 2024) = 129.4194.

Biomarin Pharmaceutical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 1.465 100.560 1.885
201409 1.295 100.428 1.669
201412 2.050 99.070 2.678
201503 2.022 99.621 2.627
201506 2.426 100.684 3.118
201509 2.530 100.392 3.262
201512 2.744 99.792 3.559
201603 2.710 100.470 3.491
201606 3.160 101.688 4.022
201609 2.715 101.861 3.450
201612 2.922 101.863 3.712
201703 2.750 102.862 3.460
201706 3.000 103.349 3.757
201709 2.989 104.136 3.715
201712 3.364 104.011 4.186
201803 3.476 105.290 4.273
201806 3.975 106.317 4.839
201809 4.534 106.507 5.509
201812 3.837 105.998 4.685
201903 4.317 107.251 5.209
201906 4.175 108.070 5.000
201909 5.108 108.329 6.102
201912 5.195 108.420 6.201
202003 6.553 108.902 7.788
202006 6.165 108.767 7.336
202009 6.512 109.815 7.675
202012 6.396 109.897 7.532
202103 7.428 111.754 8.602
202106 6.803 114.631 7.681
202109 5.889 115.734 6.585
202112 6.929 117.630 7.623
202203 6.631 121.301 7.075
202206 7.187 125.017 7.440
202209 7.139 125.227 7.378
202212 7.578 125.222 7.832
202303 7.991 127.348 8.121
202306 7.409 128.729 7.449
202309 7.509 129.860 7.484
202312 8.399 129.419 8.399
202403 8.108 129.419 8.108

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Biomarin Pharmaceutical  (BSP:B1MR34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Biomarin Pharmaceutical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=213.90/25.79
=8.29

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Biomarin Pharmaceutical was 44.11. The lowest was 7.88. And the median was 17.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Biomarin Pharmaceutical Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biomarin Pharmaceutical's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomarin Pharmaceutical (BSP:B1MR34) Business Description

Industry
Traded in Other Exchanges
Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.

Biomarin Pharmaceutical (BSP:B1MR34) Headlines

No Headlines